Key Highlights

  • OMER shares fell 16.94% in today's session to $13.86 from a prior close of $16.68.
  • Net Revenue rose 26% sequentially to $35.9 million, slightly below estimates.
  • Operating income was $4.5 million and Operating Cash Flow was $13.3 million.
  • GAAP net loss widened to $57.4 million on a non-cash derivative charge.

Omeros (NASDAQ:OMER) shares fell in today's session after the company reported third-quarter results that showed YARTEMLEA net revenue slightly below estimates. The stock was at $13.86, down 16.94% from the prior close of $16.68, on Volume of about 3.3 million shares. The shares closed down 4.63% on Monday and fell further in after-hours trading. The 52-week range runs from $6.70 to $21.24.

Omeros is a Seattle-based biopharmaceutical company founded in 1994 and led by CEO Gregory Demopulos. Its lead asset, narsoplimab, a MASP-2 inhibitor marketed as YARTEMLEA, is described by the company as the first approved therapy for transplant-associated thrombotic microangiopathy.

What Did Omeros Report for the Third Quarter?

YARTEMLEA gross sales were $41.8 million, up 30% from the second quarter, and net revenue was $35.9 million, up 26% and below the roughly $37.3 million consensus. Operating Income turned positive at $4.5 million, and operating cash flow was $13.3 million, the second consecutive positive quarter. Cash and investments were $95.3 million.

The GAAP net loss widened to $57.4 million, or $0.79 per share, on a $62 million non-cash mark-to-market charge on the derivative tied to the 2029 convertible notes. Non-GAAP adjusted Net Income was $4.7 million, or $0.06 per share, versus $1.8 million in the second quarter. July note repurchases cut the 2029 convertible principal 43% to $40.3 million, lowering potential dilution by 4.9 million shares and eliminating $8.6 million of future interest.

How Is the YARTEMLEA Launch Progressing?

A total of 109 accounts have ordered, up 49% from 73, and pharmacy and therapeutics approvals rose 25% to cover 80% of the top 40 centers. Adults account for about 70% of use. Medicare new technology add-on payment of up to $287,000 per eligible inpatient case took effect October 1, and pass-through status exempts YARTEMLEA from the 2027 340B cut to ASP minus 28%.

Management said growth continued in the fourth quarter but did not guide fourth-quarter results. Fourth-quarter operating expenses are expected slightly higher than the third quarter, with interest expense of about $6 million and income from discontinued operations of $5 million to $6 million.

Which Overhangs Remain?

Gross-to-net deductions rose to 14% of gross sales from 11.5% on higher 340B use, and management said they could approach the high teens. In October, the European Medicines Agency's CHMP issued a negative opinion on YARTEMLEA, the compassionate use program will close to new patients, and the company is pursuing approvals elsewhere.

Milestones under the Novo Nordisk (NYSE:NVO) collaboration include $100 million near term, with transition services ending in mid-2027. OMS-527 enrollment is expected in early 2027 with data in 2027.

Fourth-Quarter Sales and Gross-to-Net Trends Set the Next Checkpoints

Fourth-quarter YARTEMLEA sales growth, the gross-to-net trend and the company's plans outside Europe are the next points to watch. Guidance for 2027 will begin at some point.